Dermata Posts First $74K in Product Sales, But Cash Runs Dry by Q1 2027
DRMA sits 19% above its 52-week low of $0.603.
Summary
Dermata booked its first product revenue — $74K in Q3 2026 versus nothing a year ago — following the August 25 launch of its lead product. The top line is tiny, and the net loss widened to $2.8M from $1.7M as spending shifted toward commercialization. Cash and restricted cash fell to $5.0M at September 30 from $7.5M at year-end, and management says that funds operations only into Q1 2027, reaffirming going-concern doubt. The company also enrolled the first patient in the Tome Clearing Treatment acne trial, with launch targeted for H1 2027. With a micro-cap valuation and roughly a quarter of runway left, the next financing is the dominant risk; the August private placement raised $3.4M and the resale shares from it are now registered.
At the time of this announcement, DRMA was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.60 to $4.66. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.